masitinib   Click here for help

GtoPdb Ligand ID: 5656

Synonyms: AB-1010 | AB1010 | Masican® (proposed trade name)
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Using the trade name Masivet, this compound has been used for several years to treat mast cell tumours in dogs [6]. It is a receptor tyrosine kinase (RTK) inhibitor, with inhibitory activity at the cKIT, platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) RTKs [4].

SARS-CoV-2: Using X-ray crystallography, masitinib has been shown to bind (non-covalently) into the catalytic site of the SARS-CoV-2 3CL protease (Mpro) [3], which corresponds with detection of in vitro Mpro inhibitory activity. It does not bind to the other viral protease PLpro.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 101.63
Molecular weight 498.22
XLogP 3.41
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C
Isomeric SMILES CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C
InChI InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
Bioactivity Comments
This compound is primarily an inhibitor of type III receptor tyrosine kinases, but has some inhibitory activity at non-receptor tyrosine kinases [4].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
KIT proto-oncogene, receptor tyrosine kinase Primary target of this compound Hs Inhibitor Inhibition 8.1 pKd - 2
pKd 8.1 (Kd 8.1x10-9 M) [2]
KIT proto-oncogene, receptor tyrosine kinase Primary target of this compound Hs Inhibitor Inhibition 6.7 pIC50 - 4
pIC50 6.7 (IC50 2x10-7 M) [4]
platelet derived growth factor receptor alpha Hs Inhibitor Inhibition 6.3 pIC50 - 4
pIC50 6.3 (IC50 5.4x10-7 M) [4]
platelet derived growth factor receptor beta Hs Inhibitor Inhibition 6.1 pIC50 - 4
pIC50 6.1 (IC50 8x10-7 M) [4]